PLGA nanoparticle-based docetaxel/LY294002 drug delivery system enhances antitumor activities against gastric cancer

Abstract

Docetaxel (TXT) is acknowledged as one of the most important chemotherapy agents for gastric cancer (GC). PI3K/AKT signaling is frequently activated in GC, and its inhibitor LY294002 exerts potent antitumor effects. However, the hydrophobicity of TXT and the poor solubility and low bioavailability of LY294002 limit their clinical application. To overcome these shortcomings, we developed poly(lactic acid/glycolic) (PLGA) nanoparticles loaded with TXT and LY294002. PLGA facilitated the accumulation of TXT and LY294002 at the tumor sites. The in vitro functional results showed that PLGA(TXT+LY294002) exhibited controlled-release and resulted in a markedly reduced proliferative capacity and an elevated apoptosis rate. An in vivo orthotopic GC mouse model and xenograft mouse model confirmed the anticancer superiority and tumor-targeting feature of PLGA(TXT+LY294002). Histological analysis indicated that PLGA(TXT+LY294002) was biocompatible and had no toxicity to major organs. Characterized by the combined slow release of TXT and LY294002, this novel PLGA-based TXT/LY294002 drug delivery system provides controlled release and tumor targeting and is safe, shedding light on the future of targeted therapy against GC.

Keywords

Gastric cancer nanoparticles docetaxel LY294002 PLGA

Get full access to this article

View all access options for this article.

References

Torre

Bray

Siegel

et al . Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87–108.

Ajani

Lee

Sano

et al . Gastric adenocarcinoma. Nat Rev Dis Primers 2017; 3: 17036.

Lin

de Gooijer

Hanekamp

et al . PI3K-mTOR pathway inhibition exhibits efficacy against high-grade glioma in clinically relevant mouse models. Clin Cancer Res 2017; 23: 1286–1298.

Mohan

Vander Broek

Shah

et al . MEK inhibitor PD-0325901 overcomes resistance to PI3K/mTOR inhibitor PF-5212384 and potentiates antitumor effects in human head and neck squamous cell carcinoma. Clin Cancer Res 2015; 21: 3946–3956.

Guo

Jiao

Sui

et al . Anticancer effect of YWHAZ silencing via inducing apoptosis and autophagy in gastric cancer cells. Neoplasma 2018; 65: 693–700.

Chen

Zhao

Kang

et al . Significant suppression of non-small-cell lung cancer by hydrophobic poly(ester amide) nanoparticles with high docetaxel loading. Front Pharmacol 2018; 9: 118.

Maira

Stauffer

Schnell

et al . PI3K inhibitors for cancer treatment: where do we stand? Biochem Soc Trans 2009; 37: 265–272.

Kong

Yamori

Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy. Cancer Sci 2008; 99: 1734–1740.

Golombek

May

Theek

et al . Tumor targeting via EPR: strategies to enhance patient responses. Adv Drug Deliv Rev 2018; 130: 17–38.

10.

Matsumura

Maeda

A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986; 46: 6387–6392.

11.

Bowerman

Byrne

Chu

et al . Docetaxel-loaded PLGA nanoparticles improve efficacy in taxane-resistant triple-negative breast cancer. Nano Lett 2017; 17: 242–248.

12.

Rezvantalab

Drude

Moraveji

et al . PLGA-based nanoparticles in cancer treatment. Front Pharmacol 2018; 9: 1260.

13.

Zuo

Chen

Wang

et al . miR-337-3p suppresses the proliferation and invasion of hepatocellular carcinoma cells through targeting JAK2. Am J Cancer Res 2018; 8: 662–674.

14.

Zhang

Jiang

et al . Camptothecin derivative-loaded poly(caprolactone-co-lactide)-b-PEG-b-poly(caprolactone-co-lactide) nanoparticles and their biodistribution in mice. J Control Rel 2004; 96: 135–148.

15.

Suk

Kim

et al . PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev 2016; 99: 28–51.

16.

Zhang

Zhou

et al . Dual drug delivery and sequential release by amphiphilic Janus nanoparticles for liver cancer theranostics. Biomaterials 2018; 181: 113–125.

17.

Luo

Jiang

Ding

et al . Surfactant free delivery of docetaxel by poly[(R)-3-hydroxybutyrate-(R)-3-hydroxyhexanoate]-based polymeric micelles for effective melanoma treatments. Adv Healthcare Mater 2018; 7: e1801221.

18.

Xing

Zhu

Fan

et al . Effects of LY294002 on the invasiveness of human gastric cancer in vivo in nude mice. World J Gastroenterol 2009; 15: 5044–5052.

19.

Hirai

Sootome

Nakatsuru

et al . MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 2010; 9: 1956–1967.

20.

MacKeigan

Taxman

Hunter

et al . Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase kinase inhibition. Clin Cancer Res 2002; 8: 2091–2099.

21.

Xiao

Han

et al . Co-delivery of camptothecin and curcumin by cationic polymeric nanoparticles for synergistic colon cancer combination chemotherapy. J Mater Chem B 2015; 3: 7724–7733.

22.

Sun

Zhang

et al . Multifunctional mesoporous silica nanoparticles as efficient transporters of doxorubicin and chlorin e6 for chemo-photodynamic combinatorial cancer therapy. J Biomater Appl 2018; 32: 1253–1264.

23.

Nelson

Robinson-Hamm

Gersbach

Genome engineering: a new approach to gene therapy for neuromuscular disorders. Nat Rev Neurol 2017; 13: 647–661.

24.

Shen

Geng

et al . Folate-functionalized magnetic-mesoporous silica nanoparticles for drug/gene codelivery to potentiate the antitumor efficacy. ACS Appl Mater Interfaces 2016; 8: 13748–13758.

25.

Martínez-Negro

Kumar

Barrán-Berdón

et al . Efficient cellular knockdown mediated by siRNA nanovectors of gemini cationic lipids having delocalizable headgroups and oligo-oxyethylene spacers. ACS Appl Mater Interfaces 2016; 8: 22113–22126.

26.

Abu Lila

Ishida

Liposomal delivery systems: design optimization and current applications. Biol Pharm Bull 2017; 40: 1–10.

27.

Feng

Gao

Wang

et al . Autophagy inhibitor (LY294002) and 5-fluorouracil (5-FU) combination-based nanoliposome for enhanced efficacy against esophageal squamous cell carcinoma. Nanoscale Res Lett 2018; 13: 325.

28.

Doddapaneni

Kyryachenko

Chagani

et al . A three-drug nanoscale drug delivery system designed for preferential lymphatic uptake for the treatment of metastatic melanoma. J Control Release 2015; 220: 503–514.

29.

Ren

Sha

Yan

et al . Enhancement of radiotherapeutic efficacy for esophageal cancer by paclitaxel-loaded red blood cell membrane nanoparticles modified by the recombinant protein anti-EGFR-iRGD. J Biomater Appl 2018; 33: 707–724.

30.

Keshavarz

Moloudi

Paydar

et al . Alginate hydrogel co-loaded with cisplatin and gold nanoparticles for computed tomography image-guided chemotherapy. J Biomater Appl 2018; 33: 161–169.

31.

Jiang

Zhang

Zhou

et al . Enhancement of radiotherapy efficacy by pleiotropic liposomes encapsulated paclitaxel and perfluorotributylamine. Drug Deliv 2017; 24: 1419–1428.

32.

Liu

Qian

et al . Targeted delivery of miR-200c/DOC to inhibit cancer stem cells and cancer cells by the gelatinases-stimuli nanoparticles. Biomaterials 2013; 34: 7191–7203.